Nurix Therapeutics, Inc. (NRIX) Income Statement

The revenue trajectory is highly erratic, with a peak of $44.1M in 2025Q2 followed by a sharp contraction to single-digit millions in subsequent quarters. This pattern suggests that revenue is driven by one-time collaboration payments, not recurring commercial activity. The negative growth rates in most quarters, except for modest gains in 2025Q4 and 2025Q1, underscore the lack of a stable revenue base. Investors should monitor whether new partnerships can offset the declining trend, as the current trajectory appears unsustainable without additional deals.

The gross margin figures are highly volatile and often negative, which is atypical for a biotech. This appears to be an accounting artifact where certain R&D expenses are classified as cost of goods sold, particularly in quarters with lower revenue. For instance, in 2025Q2, COGS of $78.1M nearly matched R&D expense, suggesting that the company may be allocating a significant portion of its research costs to COGS. This makes gross margin an unreliable indicator of operational efficiency. The positive gross margin in 2026Q2 is likely due to a favorable revenue mix, but the inconsistency warrants caution when comparing margins across periods.

The company's operating expenses, particularly R&D, have remained consistently high, ranging from $48.9M to $87.7M per quarter, while revenue has not scaled correspondingly. This results in operating losses that are roughly 10 times revenue in most quarters, with no evidence of economies of scale. The lack of operating leverage is a critical concern, as it implies that even if revenue grows, the company may not achieve profitability without significant cost reductions. The negative operating margin, which reached -109.7% in 2025Q2, highlights the severity of the cost structure relative to the revenue base.

The primary cost driver is R&D, which consistently accounts for over 80% of total operating expenses. This is typical for a clinical-stage biotech, but the magnitude is substantial relative to the company's revenue. SG&A expenses have been relatively controlled, ranging from $10.7M to $15.6M, suggesting management is disciplined in administrative spending. However, the R&D intensity is a double-edged sword: it is necessary for pipeline development, but it also means that cost reductions would likely impair future growth prospects. The company's ability to manage these costs while advancing its pipeline will be crucial for its long-term viability.

The most notable inflection point in the income statement history is 2025Q2, where revenue reached $44.1M, the highest in the ten-quarter period. This spike appears to be driven by a one-time event, such as a partnership milestone, as revenue immediately fell to $18.5M in the next quarter and continued to decline. The gross margin in that quarter was -77.3%, indicating that the associated costs were also elevated, possibly due to revenue recognition rules. This inflection did not signal a change in the company's fundamental trajectory, as losses continued to widen in subsequent quarters. Investors should view such spikes with caution, as they are not indicative of recurring revenue.